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ABSTRACT
Objective: Mevalonate kinase (MVK) deficiency is a
rare autosomal recessive auto-inflammatory disorder
characterised by recurring episodes of fever associated
with multiple non-specific inflammatory symptoms and
caused by mutations in the MVK gene. The phenotypic
spectrum is wide and depends mostly on the nature of
the mutations. Hyperimmunoglobulinaemia D and
periodic fever syndrome (HIDS) is a relatively mild
presentation and predominantly associated with a
c.1129G>A (p.V377I) mutation in the MVK gene. We
report cases of two sisters homozygous for this
mutation but exhibiting distinct (symptomatic vs
asymptomatic) phenotypes.
Methods: Patient history was obtained; physical and
clinical examination and laboratory tests were
performed; lipopolysaccharide (LPS) response of
peripheral blood mononuclear cells was quantified.
Results: Low MVK enzymatic activity is not
necessarily associated with inflammatory symptoms.
Increased inflammatory cytokine secretion in response
to LPS is associated with symptomatic MVK deficiency.
Conclusions: Individuals who are homozygous for
the common p.V377I mutation in the MVK gene may
not display the characteristic inflammatory episodes
diagnostic of MKD and thus may be lost for correct
and timely diagnosis.
INTRODUCTION
Mevalonate kinase deﬁciency (MKD) is a rare
autosomal recessive autoinﬂammatory dis-
order characterised by recurring episodes of
high fever associated with multiple non-
speciﬁc inﬂammatory symptoms including
headache, arthritis, abdominal pain, diarrhoea
and skin rash.1 The disorder is caused by bial-
lelic mutations in the MVK gene and can
present with variable clinical phenotypes.2 3
The severe presentation is also known as
mevalonic aciduria (MA), and includes, in
addition to inﬂammatory episodes, develop-
mental delay, dysmorphic features, ataxia,
cerebellar atrophy, psychomotor retardation
and possibly premature death. The mild
presentation is known as hyperimmunoglo-
bulinaemia D and periodic fever syndrome
(HIDS) and characterised predominantly by
recurrent fever with inﬂammatory symp-
toms.4 Phenotypic overlap between HIDS
and MA provides evidence of a phenotypic
Key messages
What is already known about this subject?
▸ The inflammatory phenotypic spectrum of
patients carrying mutations in the Mevalonate
kinase (MVK) gene is wide and depends
mostly on the nature of the mutations.
HyperImmunoglobulinemia D and periodic fever
Syndrome (HIDS) is a relative mild presentation
and predominantly associated with a c.1129G>A
(p.V377I) mutation in the MVK gene.
What does this study add?
▸ This study describes two sisters carrying the
same homozygous c.1129G>A mutation but
exhibiting distinct (symptomatic versus asymp-
tomatic) phenotypes. This suggests the exist-
ence of modifiers loci involved in the penetrance
of HIDS.
How might this impact on clinical practice?
▸ Individuals homozygous for the common p.
V377I form of the MVK protein may not display
the characteristic inflammatory episodes diag-
nostic for Mevalonate kinase deficiency (MKD)
and thus may be lost for correct and timely
diagnosis.
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continuum between both diseases,5 which therefore cur-
rently are considered the mild and severe end of the
MKD spectrum.
During the inﬂammatory crises, high serum levels of
pro-inﬂammatory cytokines such as interleukin (IL)-1β,
tumour necrosis factor (TNF-α) and IL-6 are observed in
patients.6 Their role in the occurrence of fever is sug-
gested by the favourable therapeutic effect of the TNF-α
inhibitor etanercept.7 IL-1β is the prototypical proinﬂam-
matory cytokine and plays an important role in the patho-
genesis of several autoinﬂammatory diseases, including
tumour necrosis factor-1 receptor-associated periodic syn-
drome and cryopyrin-associated periodic syndromes. IL-1β
is produced on pro-IL-1β cleavage by caspase-1, a process
that requires activation of inﬂammasomes, which are
responsible for the activation of caspase-1.8 It has been
established that the MKD-dependent inﬂammation results
from a shortage of the isoprenoid geranylgeranyl-PP.9
Furthermore, it has also been shown that unprenylated
RhoA is involved in IL-1β hypersecretion in the MKD deﬁ-
ciency model through stimulation of Rac1 activity. A
pivotal role for RhoA in MKD-associated autoinﬂamma-
tion through Rac1/PKB signalling toward interleukin 1β
production has been identiﬁed, which partly clariﬁes the
link between MVK deﬁciency and increased IL-1β
secretion.10
We report the cases of two sisters, both homozygous
for the most common V377I mutation causing HIDS,
but of whom only one exhibited inﬂammatory
symptoms.
CASE REPORT
Clinical description of the patient
The proposita (patient 1), a 43-year-old woman with a
history of depression and ophthalmic abnormalities
(optic neuritis) was examined in the rheumatology
clinic because of polyarthralgias involving the ﬁngers,
wrists and ankles, and disturbed night sleep. She was
married and had two children who had not presented
any medical problems up to the time of her examin-
ation. The patient reported of diffuse pain concerning
joints and muscles but clinical examination revealed
absence of synovitis and neurological examination was
normal. She presented central allodynia and hyperalgae-
sia. She also reported of visual ﬁeld alteration. Other
symptoms included frequent right upper abdominal
pains, nausea, vomiting and fatigue. She presented no
sign of autoimmune diseases: no Raynaud syndrome, no
dry syndrome, no photosensitivity, no thromboembolic
episode, no miscarriage, no nettle rash, no other inﬂam-
matory cutaneous lesions, no fever or other systemic
manifestation, no headache and no chest pain. Yet,
small cervical infracentimetric painless lymphadenopa-
thies were present.
On the ﬁrst evaluation, blood cell count was normal,
no inﬂammatory syndrome was found, C reactive
protein level was below 4 mg/L, antinuclear antibodies
titre was 1/320 and rheumatoid factors were not
detected. HIV, viral hepatitis (HBV, HCV) and Lyme
disease serologies were negative. In contrast, serum
protein immunoﬁxation electrophoresis revealed abnor-
mal levels of polyclonal IgD, which was quantitatively
conﬁrmed by nephelometry (690 UI/mL, table 1). IgA
levels were quantiﬁed at 5.82 U/mL. CT of the chest,
abdomen and pelvis was normal, in particular, neither
splenomegaly nor adenopathy was observed.
Ophthalmological examination and visual evoked poten-
tial recording revealed conduction troubles of the right
eye optic nerve. At this stage, prescription of low-dose
corticoids (20 mg/day) later supplemented with metho-
trexate (10 mg/week) did not show any efﬁcacy. Despite
the absence of (periodic) fever, mutations in the MVK
gene encoding mevalonate kinase were searched. To this
end, exons and intron/exon junctions of the MVK gene
were ampliﬁed and sequenced. This revealed the homo-
zygous presence of the c.1129G>A (p.V377I) mutation,
which is found in >90% of patients with the HIDS
phenotype. The patient was then placed under anti IL-1
therapy (kineret 100 mg/day), which provided a subject-
ive improvement (reduction of the joint pain), with
amelioration of neither the ophthalmic manifestation
nor the adenopathies.
Biochemical studies
For these studies, blood samples and skin biopsies were
obtained from patients and controls attending the
Department of Rheumatology, Hôpitaux Civils de
Colmar (France), and were collected during routine
clinical procedures. All participants gave their informed
consent and the study was approved by the Ethics
Committee of Strasbourg University Hospital.
Because the patient did not exhibit recurrent symptoms
and showed neither fever nor biological inﬂammatory
signs, testing for MVK activity in circulating lymphocytes
was performed using a radiometric assay based on the
quantiﬁcation of the phosphorylated products of
14C-mevalonic acid, as previously described.11 In addition,
urinary mevalonic acid extraction was performed by gas
phase chromatography coupled with mass spectrometry.
MVK enzymatic activity in lymphocytes was drastically
reduced to 0.3 µkat/kg prot (2.5< normal range
<7.8 μkat/kg) and urinary mevalonic acid concentration
was found twice above normal values (3.1 and 4.1 mmol/
mol creatinine). Based on the clinical presentation and
combined laboratory results, HIDS was diagnosed.
The atypical clinical presentation of HIDS without
fever and other recurrent inﬂammatory symptoms
prompted us to investigate the whole family. The parents
were not consanguineous and their ethnic background
was Caucasian. The patient had one sister and one
brother (ﬁgure 1). Table 1 summarises the biological
parameters of four family members; the brother was not
available for follow-up. Interestingly, the sister, who was
40 years old, had no history of disease and no inﬂamma-
tory signs, but carried the same homozygous p.V377I
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mutation, had a similar decrease in MVK enzyme activity
in lymphocytes (0.3 µkat/kg prot), and elevated serum
levels of IgD (140 U/mL) and IgA (2.5 U/mL). In light
of these results, thorough clinical examination was per-
formed, but no symptoms compatible with HIDS were
found (no abdominal pain, no vomiting, no aphthous
stomatitis, no maculopapular rash, no recurrent head-
ache, no myalgia and no lymph node enlargement).
The father (67 years old) had a history of ischaemic
cardiopathy and chronic bronchopulmonary obstructive
disease, but never experienced recurrent fever, arthritis
or other systemic symptoms. Genetic analysis conﬁrmed
carriership for the V377I mutation. In accordance with
this, the MVK activity in lymphocytes and the urinary
mevalonic acid concentration were normal, and serum
IgD and IgA levels were low. The mother (69 years old
and asymptomatic) was also a carrier for the V377I
mutation and showed normal urinary mevalonic acid
concentrations, and low serum IgD and IgA levels. No
inﬂammatory signs were detected.
To further investigate the effect of the mutation on MVK
enzyme activity, we analysed ﬁbroblasts obtained from skin
biopsies of the different family members and controls, and
cultured in Nutrient Mixture Ham’ s F-10 with L-glutamine
and 25 mM HEPES supplemented with 10% fetal calf
serum at room temperature. MVK activity was measured in
ﬁbroblast cell lysates using C-labelled mevalonate (NEN,
Perkin Elmer) as previously described.12
In accordance with their carrier status and as previ-
ously documented (10), the heterozygous parents
showed MVK activities that comprise ∼30% of the activ-
ities in control ﬁbroblasts. The MVK activities measured
in the cells of the patient and her asymptomatic sister
comprised 3% and 6.5%, of the activities in control
ﬁbroblasts, which are both within the range normally
observed for patients with HIDS (10).
Pro-inflammatory cytokine response of lipopolysaccharide
(LPS)-stimulated peripheral blood mononuclear cells
We investigated the cytokine response of peripheral
blood mononuclear cells (PBMCs) isolated from
Figure 1 Pedigree of the HIDS family. The black circle
corresponds to the symptomatic patient carrying the
homozygous mutation. Squares correspond to males. wt,
wild-type allele. HIDS, hyperimmunoglobulinaemia D and
periodic fever syndrome.
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different members of this family to evaluate if these were
different. PBMCs were stimulated with LPS (1 μg/mL,
Salmonella abortus equi LPS from Sigma) for 6 h and cyto-
kine (IL-6, IL-1β, TNF-α) release was measured by ELISA
(R&D Systems) in culture supernatants. LPS-stimulated
PBMCs from the symptomatic patient 1 released large
amounts of IL-6 (27 000 pg/mL) while those of her
asymptomatic sister (subject 1) released lower quantities
of this cytokine (18 000 pg/mL, ﬁgure 2A). Similar obser-
vations were made for TNF-α (ﬁgure 2B) and IL-1β
(ﬁgure 2C). Altogether, these results indicate differential
inﬂammatory responses in cells isolated from the HIDS
symptomatic subject compared to her healthy sister. In
this assay, values represent the mean±SD. Two-tailed
Mann-Whitney test was used to compare two
independent groups using GraphPad software. A prob-
ability (p) value <0.05 was considered signiﬁcant.
DISCUSSION
In this report, we describe two sisters, aged 43 and
40 years, who were both homozygous for the p.V377I
mutation in the MVK gene, which is found in 90% of
HIDS patients. The vast majority of these are compound
heterozygous for this mutation and a second severe
mutation, however, and homozygotes are rarely found,
based on which it had been hypothesised previously that
a majority of homozygotes may be asymptomatic or
present with a less severe inﬂammatory phenotype.13
Our ﬁndings now conﬁrm this hypothesis. Indeed,
Figure 2 Proinflammatory
cytokine production by
LPS-activated PBMC from patient
1 (symptomatic), patient 2
(asymptomatic), patient 3
(asymptomatic) and two unrelated
controls. Cells were stimulated
with LPS (1 μg/mL) for 6 hours.
(A-C) Cytokine levels in the cell
culture supernatant were
quantified by ELISA. Values are
the mean of 3 experiments±SD.
*p<0.05; **p<0.01 (Mann-Whitney
U test). Statistical analysis
comparing P1 and other
participants or controls gave
similar results. PBMC, peripheral
blood mononuclear cells.
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although biochemical studies in cells from both sisters
revealed markedly decreased MVK activities that were
within the range typically observed in patients with
HIDS, only one of the sisters showed clinical symptoms,
including arthralgia, optical neuritis and lymphadenopa-
thies, while the other sister was asymptomatic. Moreover,
the symptomatic sister never presented with recurrent
episodes of fever, which is considered a diagnostic hall-
mark of MKD, including in HIDS.14 In both sisters,
increased levels of IgD were observed, which is compat-
ible with but not diagnostic, per se, for HIDS. This
observation is in line with another recent report describ-
ing absence of symptoms in participants carrying a
homozygous p.V377I mutation.15 However, in the latter
case, asymptomatic children were also carriers for MEFV
mutations p.E148Q, p.P369S and p.R408Q. In addition,
our work strengthens recent observations indicating that
MKD, while very unlikely in patients with a normal
mevalonic acid excretion, cannot be excluded
completely.16
Homozygosity for the pV377I mutation does result in
an augmented pro-inﬂammatory response of
LPS-stimulated PBMCs when compared to control
PBMCs. Interestingly, we noted that the TNF-α, IL-6 and
IL1-β secretion by cells isolated from patient 1 was
higher than observed for her asymptomatic sister
(patient 2), her mother (patient 3) or 2 genetically
unrelated controls, which may reﬂect a higher risk for
developing inﬂammation or a pre-primed immuno-
logical status of the patient. The father (patient 4) was
not tested in this assay because of its elevated erythro-
cyte sedimentation rate (ESR, table 1) at the time of
blood sampling.
To conclude, our report indicates that individuals
who are homozygous for the common p.V377I muta-
tion may not display the characteristic inﬂammatory
episodes diagnostic for MKD. Such patients who do
not follow the gold standard with respect to clinical
presentation14 could thus be lost for correct and
timely diagnosis.
To gain further insights into the molecular basis under-
lying the phenotypic discrepancies between patients 1
and 2 and possibly identify genetic modiﬁers, further
studies involving multi-OMICS analyses—including whole
exome sequencing, transcriptomic and proteomic ana-
lysis—are ongoing.
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